Pfizer Inc. chief development officer William Pao joined the big pharma just over one year ago to oversee the company’s clinical drug development, a change following his lengthy career in early research, initially in academia and more recently at Roche.
Pao, in an interview at the company’s new New York City headquarters in June, talked about the transition to Pfizer, the company’s late-stage pipeline and one of his top
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?